https://pepsreview.com/articles/korea-approves-hanmi-eppe-first-homegrown-glp-1-obesity-drug PepsReview en 2026-10-08 GLP-1, efpeglenatide, Hanmi Pharmaceutical, EPPE approval, Korea MFDS, obesity drug, weight loss drug 2026 https://pepsreview.com/articles/uk-asa-bans-first-ads-oral-glp-1-weight-loss-medicines PepsReview en 2026-10-08 ASA, oral GLP-1, weight loss drug ads, MHRA, prescription-only medicine, Wegovy tablet, UK regulation https://pepsreview.com/articles/glp-1-hair-loss-nail-changes-two-new-studies PepsReview en 2026-10-08 GLP-1 side effects, hair loss, nail detachment, EADV 2026, semaglutide, scalp inflammation, weight loss drugs https://pepsreview.com/articles/novo-nordisk-halves-wegovy-us-list-price PepsReview en 2026-10-08 Novo Nordisk, Wegovy price cut, Ozempic price, GLP-1 pricing, semaglutide cost, obesity market, US drug prices https://pepsreview.com/articles/retatrutide-triumph-1-results-published-phase-3-25-percent-weight-loss PepsReview en 2026-10-07 retatrutide, TRIUMPH-1, obesity drug, GLP-1, triple agonist, weight loss trial, peptide research, Eli Lilly https://pepsreview.com/articles/fda-weight-loss-drugs-diabetes-approved-list-2026 PepsReview en 2026-10-07 GLP-1, semaglutide, tirzepatide, liraglutide, orforglipron, FDA approval, weight loss drugs, type 2 diabetes https://pepsreview.com/articles/hundreds-of-glp-1-injury-lawsuits-now-flood-new-jersey-courts PepsReview en 2026-10-06 GLP-1 lawsuits, Ozempic lawsuit, New Jersey MCL, Bergen County, gastroparesis, Wegovy, Mounjaro, drug litigation https://pepsreview.com/articles/lillys-foundayo-meets-heart-safety-goals-largest-type-2-diabetes-trial PepsReview en 2026-10-06 Foundayo, orforglipron, ACHIEVE-4, oral GLP-1, type 2 diabetes, cardiovascular safety, Eli Lilly, weight loss